FDA approves Incyte's treatment for chronic graft-versus-host disease-February 2024-www.financetom.com

FDA approves Incyte's treatment for chronic graft-versus-host disease

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

FDA approves Incyte's treatment for chronic graft-versus-host disease

Aug 14, 2024 12:58 PM

Aug 14 (Reuters) - The U.S. Food and Drug Administration

on Wednesday approved drugmaker Incyte Corp's ( INCY ) treatment

for a type of graft-versus-host disease (GvHD).

GvHD is a systemic disorder that occurs when immune cells

from transplanted tissue recognize the recipient's body as

foreign and attack its cells.

Previous page： Michigan lowers incentives for Ford EV battery plant to match reduced output Next page： Germany in deal to cut Huawei's role in 5G wireless network, sources say

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Michigan lowers incentives for Ford EV battery plant to match reduced output

Jul 10, 2024

(This July 9 story has been corrected to say that Mike Gallagher is now a former member of Congress, in paragraph 7) By Nora Eckert DETROIT (Reuters) - Ford Motor ( F ) is receiving a reduced incentive package from Michigan for its battery plant in the city of Marshall after the automaker cut expected production at the facility to...

Germany in deal to cut Huawei's role in 5G wireless network, sources say

Jul 10, 2024

BERLIN, July 10 (Reuters) - The German government and mobile phone carriers have agreed in principle on steps to phase components by Chinese technology companies out of the nation's 5G wireless network over the next five years, two people familiar with the matter told Reuters on Wednesday. Newspaper Sueddeutsche Zeitung as well as broadcasters NDR and WDR earlier jointly reported...

Correction: Top Midday Stories: TSM June Revenue Jumps 33% YoY; Honeywell to Buy Air Products' LNG Process Tech; Microsoft, Apple Abandon Seats on OpenAI Board; AMD to Acquire Silo AI

Jul 10, 2024

12:07 PM EDT, 07/10/2024 (MT Newswires) -- (Corrected third paragraph and headline to show that Honeywell ( HON ) agreed to acquire the LNG process technology and equipment business of Air Products and Chemicals ( APD ).) All three major US stock indexes were up around midday trading Wednesday, as Federal Reserve Chair Jerome Powell embarks on a second day...

United Therapeutics Says Idiopathic Pulmonary Fibrosis Treatment Study Reaches Full Enrollment

Jul 10, 2024

12:13 PM EDT, 07/10/2024 (MT Newswires) -- United Therapeutics ( UTHR ) said Wednesday its late-stage study of Tyvaso inhalation solution to treat idiopathic pulmonary fibrosis has reached full enrollment. The 597-patient TETON 2 study will evaluate the safety and efficacy of nebulized Tyvaso in subjects with idiopathic pulmonary fibrosis over a 52-week period at sites outside of the US...